Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.25 (71.37% upside)

Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016Jefferies GroupBoost Price TargetBuy$61.00 -> $62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Brean CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Credit Suisse Group AGReiterated RatingOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.39)($0.40)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414$0.21($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2($0.25)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/18/2014Q1($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.74)($0.66)($0.71)
Q2 20162($0.80)($0.78)($0.79)
Q3 20162($0.89)($0.83)($0.86)
Q4 20162($1.09)($0.88)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateHeadline
07/27/16 11:02 AMAlder BioPharmaceuticals Inc. (ALDR) Jumps 6.13% on July 25 - Equities.com
07/27/16 08:27 AMHere’s What’s Important About Alder Biopharmaceuticals Inc (ALDR)’s Latest Release -
07/27/16 02:56 AMEdited Transcript of ALDR earnings conference call or presentation 26-Jul-16 9:00pm GMT -
07/26/16 08:29 PMMigraine treatment company Alder reports loss, spends more on research
07/26/16 08:29 PMAlder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results
07/26/16 08:29 PMAlder BioPharmaceuticals : posts 2Q loss
07/26/16 04:53 PMAlder BioPharmaceuticals posts 2Q loss -
07/26/16 02:25 PMHere's What's Important About Alder Biopharmaceuticals Inc ... - Market Exclusive
07/26/16 11:57 AMAlder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b
07/26/16 11:57 AMHere’s What’s Important About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s Latest Release
07/26/16 06:07 AMQ2 2016 Alder Biopharmaceuticals Inc Earnings Release - After Market Close -
07/25/16 08:28 PMAlder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b - StreetInsider.com
07/25/16 02:57 PMAlder BioPharma Confirms Data For Chronic Migraine Candidate ALD403
07/25/16 01:42 PMAlder Biopharma Migraine Drug Holds Up After 6 Months -
07/25/16 07:00 AMAlder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine - [GlobeNewswire] - BOTHELL, Wash., July 25, 2016-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced top-line 24- week data demonstrating ...
07/23/16 02:23 PMStock Up Nicely This Week: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - TGP
07/23/16 02:23 PMIs $61 Price Target Attainable For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)? - Investor Newswire
07/23/16 06:52 AMCormorant Asset Management LLC Increased Alder ... - Press Telegraph
07/19/16 07:00 AMAlder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results - [GlobeNewswire] - BOTHELL, Wash., July 19, 2016-- Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its second quarter ...
07/18/16 02:28 PMMetLife, Inc. (NYSE:MET) Went Up 0.54%: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Global Ship Lease, Inc ... - KC Register
07/18/16 07:15 AMShares of Alder BioPharmaceuticals (ALDR) Drops by -4.19% - Trade Calls
07/17/16 07:09 AMAlder BioPharmaceuticals, Inc. (ALDR) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 02:23 PMIncreased Volatility Noted on Shares of: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily
07/16/16 02:23 PMShares Experiencing a Downtrend: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - TGP
07/16/16 02:23 PMStrong Sell Calls For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) At 0 - Investor Newswire
07/15/16 04:01 PMALDER BIOPHARMACEUTICALS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders -
07/15/16 12:59 PMAlder BioPharmaceuticals, Inc. (ALDR) Updated Price Targets - FTSE News
07/14/16 07:53 PMAlder BioPharmaceuticals Inc. (ALDR) Drops 5.92% on July 13 - Equities.com
07/14/16 11:20 AMNew Broker Ratings For Alder BioPharmaceuticals, Inc. (ALDR) - FTSE News
07/13/16 10:29 AMAlder Biopharmaceuticals Incorporated (NASDAQ:ALDR) Short Interest Increased By 14.89% - Consumer Eagle
07/12/16 02:27 PMShares Moving Up Over the Past Quarter: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily
07/11/16 07:12 AMStock on the Rise for the Quarter: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily
07/10/16 02:23 PMNext Weeks Broker Price Targets For Alder BioPharmaceuticals, Inc. (ALDR) - Fiscal Standard
07/10/16 07:12 AMIs $61 Within Reach For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)? - Investor Newswire
07/09/16 10:30 AMCormorant Asset Management LLC Increased Alder Biopharmaceuticals INC (NASDAQ:ALDR) by $17.76 Million as ... - Press Telegraph
07/07/16 02:25 PMInsiders are Gradually Selling Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Telanagana Press
07/07/16 02:25 PMAlder BioPharmaceuticals (ALDR) : Analyst Rating Update - Trade Calls
07/06/16 07:12 AMBroker Outlook For Alder BioPharmaceuticals, Inc. (ALDR) - Fiscal Standard
07/04/16 07:12 AMAlder Biopharmaceuticals Incorporated (NASDAQ:ALDR) Shorted Shares Increased 14.89% After Market Selling - Press Telegraph
07/03/16 07:12 AMAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Expected to Reach Highs Of $61 - Investor Newswire
06/29/16 07:32 PMAlder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer - GlobeNewswire (press release)
06/29/16 02:22 PMAlder BioPharmaceuticals Appoints Timothy M. Whitaker, MD, Chief Medical Officer - GlobeNewswire (press release)
06/29/16 02:22 PMAlder BioPharmaceuticals Inc. (ALDR) Jumps 5.15% on June 28 - Equities.com
06/29/16 07:11 AMAlder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer - [at noodls] - BOTHELL, Wash., June 29, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the ...
06/25/16 02:25 PMStock Tracing Lower on the Week Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily
06/25/16 02:25 PMStrong Sell Calls Recommendations For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) At 0 - Investor Newswire
06/25/16 02:25 PMAnalysts Spotlight: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , Fibrocell Science Inc (NASDAQ:FCSC) - Street Updates
06/23/16 03:53 PMAlder BioPharmaceuticals Inc. (ALDR) Drops 6.78% on June 21 - Equities.com
06/21/16 02:22 PMRecently Issued Stock Ratings For Alder BioPharmaceuticals, Inc. (ALDR) - Fiscal Standard
06/20/16 02:24 PMStock on Trader's Radar: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - iStreetWire

Social

About Alder BioPharmaceuticals

Alder BioPharmaceuticals logoAlder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDR
  • CUSIP:
Key Metrics:
  • Previous Close: $30.49
  • 50 Day Moving Average: $26.66
  • 200 Day Moving Average: $25.11
  • P/E Ratio: N/A
  • P/E Growth: -0.39
  • Market Cap: $1.52B
  • Beta: 2.53
  • Current Year EPS Consensus Estimate: $-3.29 EPS
  • Next Year EPS Consensus Estimate: $-3.48 EPS
Additional Links:
Alder BioPharmaceuticals (NASDAQ:ALDR) Chart for Thursday, July, 28, 2016